May. 2, 2020

CDC launches national viral genomics consortium to better map SARS-CoV-2 transmission

 

CDC launches national viral genomics consortium to better map SARS-CoV-2 transmission

Rapid release of open coronavirus sequence data will help guide COVID-19 public health response, drive innovation and discovery, and advance understanding of this and future pandemics

 

 

CDC has kicked off the SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance (SPHERES) consortium, which will greatly expand the use of whole genome sequencing (WGS) of the COVID-19 virus.

This national network of sequencing laboratories will speed the release of SARS-CoV-2 sequence data into the public domain.

SPHERES will provide consistent, real-time sequence data to the public health response teams investigating cases and clusters of COVID-19 across the country. It will help them better understand how the virus is spreading, both nationally and in their local communities. Better data, in turn, will help public health officials interrupt chains of transmission, prevent new cases of illness, and protect and save lives.

“The U.S. is the world’s leader in advanced rapid genome sequencing. This coordinated effort across our public, private, clinical, and academic public health laboratories will play a vital role in understanding the transmission, evolution, and treatment of SARS-CoV-2. I am confident that our finest, most skilled minds are working together to help us save lives today and tomorrow,” said CDC Director Robert Redfield, M.D.

 

Tracking the COVID-19 virus as it evolves

Genomic sequence data can give unprecedented insight into the biology of SARS-CoV-2, the virus that causes COVID-19, and help define the changing landscape of the pandemic. By sequencing viruses from across the United States, CDC and other public health authorities can monitor important changes in the virus and use this information to guide contact tracing, public health mitigation efforts, and infection control strategies.

The SPHERES consortium is an ambitious effort to coordinate SARS-CoV-2 genome sequencing nationally, organizing dozens of smaller, individual efforts into a single, distributed network of laboratories, institutions and corporations. The consortium combines the expertise, technology, and resources of 40 state and local public health departments, several large clinical laboratories, and over two dozen collaborating institutions across the federal government, academia, and the private sector.

SPHERES will establish best practices and consensus data standards, accelerate open data sharing, and establish a pool of resources and expertise to help bring cutting-edge technology to the national COVID-19 response.

 

SPHERES data open, shared

Consortium members share a commitment to rapid open sequence sharing. They plan to submit all useful sequence data into public repositories at the National Library of Medicine’s National Center for Biotechnology Information (NLM/NCBI), the Global Initiative on Sharing Avian Influenza Data (GISAID), and other public sequence repositories. This will help ensure that that viral sequence data from across the United States is rapidly available for public health decision making and freely accessible to researchers everywhere.

 

Consortium members include:

Federal agencies and laboratories

Centers for Disease Control and Prevention, Office of Advanced Molecular Detections

Argonne National Laboratory

Defense Health Agency, Global Infectious Disease Surveillance

Food and Drug Administration

Lawrence Berkeley National Laboratory

Los Alamos National Laboratory

National Institute of Allergy and Infectious Diseases, Office of Genomics and Advanced Technology

National Institute of Standards and Technology

National Library of Medicine’s National Center for Biotechnology Information

Walter Reed Army Institute of Research

 

State/local public health laboratories
Arizona                       North Carolina
California                    New Mexico
Delaware                     North Dakota
District of Columbia   Nevada
Florida                        New York
Hawaii                        Utah
Massachusetts             Virginia
Maine                          Washington
Maryland                    Wisconsin
Michigan                     Wyoming
Minnesota

 

Academic Institutions

Baylor University

University of California, Los Angeles

Cornell University

University of California, San Francisco

Fred Hutchinson Cancer Research Center

University of California, Santa Cruz

Mount Sinai School of Medicine

University of Chicago

New York University

University of Maryland

Northern Arizona University

University of Minnesota

University of Buffalo

University of Nebraska

University of California, Berkeley

University of New Mexico

University of California, Davis

University of Washington

University of California, Irvine

Yale University

 

Corporations*

Abbott Diagnostics

LabCorp

bioMérieux

One Codex

Color Genomics

Oxford Nanopore Technologies

Gingko Bioworks

Pacific Biosciences

IDbyDNA

Qiagen

In-Q-Tel

Quest Diagnostics

Verily Life Sciences

 

 

*Names of corporations are provided for information purposes only, and their inclusion here does not constitute an endorsement of the corporations or any of their commercial products or services by the U.S. Centers for Disease Control and Prevention.

 

Non-profit public health or research institutes

Association of Public Health Laboratories

Public Health Alliance for Genomic Epidemiology

Bill and Melinda Gates Foundation

Scripps Research

Broad Institute

The Jackson Laboratory

Chan Zuckerberg BioHub

Translational Genomics Research Institute - North

J. Craig Venter Institute

Walder Foundation

 

For the past six years, CDC’s Office of Advanced Molecular Detection program has invested in federal and state public health laboratories to expand the use of pathogen genomics and other advanced laboratory technologies for infectious disease surveillance and outbreak response. The current consortium investment aims to save lives in the SARS-CoV-2 pandemic and prepare the United States and the world for future pandemic response.

To learn more about genomic sequencing or CDC’s work in advanced molecular detection, visit https://www.cdc.gov/amd/